FDA approves Dupixent (dupilumab) as treatment for chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a clinical condition characterized by prolonged inflammation (more than 12 weeks) of the nose and paranasal sinuses. Signs and symptoms of sinusitis include headache, swelling of […]
Posted on